Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.

To compare urinary, bowel, and sexual health-related quality-of-life (HRQOL) changes due to high-dose-rate (HDR) brachytherapy, low-dose-rate (LDR) brachytherapy, or intensity-modulated radiation therapy (IMRT) monotherapy for prostate cancer.

Between January 2002 and September 2013, 413 low-risk or favorable intermediate-risk prostate cancer patients were treated with HDR brachytherapy monotherapy to 2700-2800 cGy in two fractions (n = 85), iodine-125 LDR brachytherapy monotherapy to 14,500 cGy in one fraction (n = 249), or IMRT monotherapy to 7400-8100 cGy in 37-45 fractions (n = 79) without pelvic lymph node irradiation. No androgen deprivation therapy was given. Patients used an international prostate symptoms score questionnaire, an expanded prostate cancer index composite-26 bowel questionnaire, and a sexual health inventory for men questionnaire to assess their urinary, bowel, and sexual HRQOL, respectively, pretreatment and at 1, 3, 6, 9, 12, and 18 months posttreatment.

Median follow-up was 32 months. HDR brachytherapy and IMRT patients had significantly less deterioration in their urinary HRQOL than LDR brachytherapy patients at 1 and 3 months after irradiation. The only significant decrease in bowel HRQOL between the groups was seen 18 months after treatment, at which point IMRT patients had a slight, but significant, deterioration in their bowel HRQOL compared with HDR and LDR brachytherapy patients. HDR brachytherapy patients had worse sexual HRQOL than both LDR brachytherapy and IMRT patients after treatment.

IMRT and HDR brachytherapy cause less severe acute worsening of urinary HRQOL than LDR brachytherapy. However, IMRT causes a slight, but significant, worsening of bowel HRQOL compared with HDR and LDR brachytherapy.

Brachytherapy. 2015 Oct 06 [Epub ahead of print]

Tobin J Strom, Alex A Cruz, Nick B Figura, Kushagra Shrinath, Kevin Nethers, Eric A Mellon, Daniel C Fernandez, Amarjit S Saini, Dylan C Hunt, Randy V Heysek, Richard B Wilder

Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Cancer Treatment Centers of America, Newnan, GA. 

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe